Her Fiancé Fired Her During the Shareholder Vote—Then the Prototype Responded Only to Her Voice

Part 2

Synapse Motion began in my father’s garage with a bicycle brake cable, two discarded motors, and Graham holding a fire extinguisher.

We were twenty-five. I was a biomedical engineer with student debt and an obsession with neural adaptation. Graham was a business-school dropout who understood how to make skeptical people listen.

The first prototype helped my father move his right leg after a stroke. It was clumsy, loud, and beautiful.

Graham found our first rehabilitation partner. I wrote the code. He slept on the garage floor during testing and learned enough anatomy to ask useful questions. We fell in love between grant rejections.

Then my father’s condition worsened.

During three months of hospital visits, Graham and Miles brought papers for temporary patent administration, emergency financing, and corporate conversion. I signed where my brother Ben told me the company needed authority to file deadlines.

Ben was a new patent attorney then. He reviewed draft versions.

The executed versions were different.

After the shareholder disaster, Ben compared the files. Pages granting temporary administration had been replaced with permanent assignment language transferring my patents to Synapse Motion for one dollar and “continued employment consideration.”

The papers I signed during my father’s illness had been converted into a permanent transfer.

My signature was real. The document structure was not.

Graham came to my apartment that night.

“I did not know the pages were changed,” he said.

“Did you know Miles wanted me removed?”

He stopped.

“Yes.”

The admission hurt more than the paperwork.

“He said the acquisition committee would not proceed while you controlled the creator key,” Graham continued. “I thought I could let the deal close, restore your role, and protect the company.”

“You fired me in public.”

“Temporarily.”

“You ended our engagement into a live microphone.”

“I panicked.”

“You chose investors before you panicked.”

Graham knew the plan required my removal. He simply believed he could reverse the betrayal after collecting its benefits.

I contacted every patient using a Synapse device. Regulators might shut down the network if unauthorized code or ownership fraud threatened safety. Patients needed instructions for manual operation and emergency support.

Miles accused me of creating panic.

Victor joined a group call from his home. “The panic began when you tried to sell the software behind our bodies.”

The patients understood the stakes better than shareholders. Synapse devices learned from gait patterns, muscle signals, facial responses to pain, and home-environment data. A surveillance buyer could use that system to identify individuals by movement, expression, or neurological behavior.

Graham reviewed the Argus term sheet and finally saw the hidden schedule. Miles negotiated rights to “behavioral inference modules” and “identity-resolution capability.”

“I never approved this language,” Graham said.

“You approved an acquisition without reading the technical annex.”

He flinched. The pattern was familiar: powerful men signing what experts placed before them, then calling themselves manipulated when consequences appeared.

Jae Foster, our lead programmer, had remained silent during my firing. He avoided my calls for two days. I assumed Miles bought him.

Then he arrived at Ben’s office with three encrypted drives.

“Someone inserted facial-recognition libraries into the mobility software,” Jae said. “They hid the commits under accessibility updates.”

“Who?”

“Credentials say me.”

“Did you write them?”

“No. I copied everything before they locked me out.”

The code did not merely recognize faces. It linked expressions, gait, and household-camera feeds to individual profiles.

Argus was not buying a rehabilitation company.

It was buying a population-scale biometric engine trained on people who believed the device existed to help them move.

The day after the shareholder vote, Victor invited me to his rehabilitation center. I expected questions about the device. Instead, twelve patients waited in a circle with printed copies of Synapse’s new privacy terms.

“Page nine says the company may analyze environmental imagery,” one woman said. “Does that mean the camera in my bedroom?”

“It can,” I answered.

Graham had approved the policy while I was caring for my father. I had reviewed the technical safeguards but not the final legal language. My own absence had become part of the gap, though it did not justify Miles altering patents or using data beyond consent.

Victor tapped the metal support at his knee. “We are not only users. The machine learns from us. Who owns what it learns?”

The company’s answer was buried in another clause: Synapse owned derivative models created from patient activity.

I spent the afternoon explaining what I knew and writing down what I did not. The patients refused the passive role the board assigned them. They formed a committee, selected counsel, and demanded direct access to safety updates.

Graham arrived near closing.

Victor blocked the doorway with his wheelchair. “You can enter if you answer questions without a presentation.”

Graham removed his suit jacket and sat in the circle.

A patient asked why he fired me.

“Because investors told me the company needed one decision-maker,” he said.

“Did you think that decision-maker should be you?”

“Yes.”

“Why?”

Graham looked toward me, then away. “Because I confused raising money with creating the product.”

It was not enough, but it was honest.

Ben’s patent review revealed that my father had signed one document as a witness during a lucid period after his stroke. Miles used that signature to make the altered assignment appear reviewed by family counsel. My father died believing he helped protect my invention.

I took the document to his grave and sat on the wet grass longer than dignity required. Graham came only after Ben told him I had been there for hours.

He remained several yards away.

“I should have protected the original pages,” he said.

“You should have protected me while I was too tired to protect anything.”

“Yes.”

“I do not need you to explain that Miles was stronger then.”

“I was not weak. I was ambitious.”

That answer stayed with me.

The acquisition documents revealed why Miles needed my creator authorization removed before closing. Argus would not accept a license dependent on one engineer’s revocable key. The buyer demanded either permanent assignment or evidence that Synapse could operate without me.

My public firing was designed to prove both governance control and technical independence. The prototype’s refusal destroyed that representation in front of shareholders.

Miles responded by arguing the creator lock itself was a safety defect. Regulators asked why one person held emergency authority over thousands of devices.

The criticism was valid. I had built the key when Synapse was a garage project and never replaced it with shared clinical governance. My intention protected patients from hostile takeover, but concentration created another risk.

Rosa insisted we address that honestly rather than defend every design because Miles attacked it.

“Being right about the conspiracy does not make every old decision right,” she said.

We proposed a temporary three-key system requiring patient, clinical, and technical approval. The change became the model later used by the cooperative.

Graham watched the regulators accept my proposal.

“You solved the problem they used to remove you,” he said.

“I acknowledged a problem without surrendering ownership of the truth.”

He looked down. “I should have known the difference.”